Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

EAU 2023: Treatment landscape for early-stage bladder cancer

EAU 2023

10 - 13 Mar 2023

Published: 16 Mar 2023

Views: 331

Rating:

Save

Dr Bernadett Szabados, Prof Rob Jones, Dr Félix Guerrero-Ramos and Dr Cosimo De Nunzio

Dr Bernadett Szabados (Queen Mary University of London, London, UK), Prof Rob Jones (The University of Glasgow, Glasgow, UK), Dr Félix Guerrero-Ramos (Hospital Universitario 12 de Octubre, Madrid, Spain) and Dr Cosimo De Nunzio (Sant'Andrea Hospital, University La Sapienza, Rome, Italy) discuss the debates in early-stage bladder cancer.

The panel talks about the management of patients and current treatments in early-stage bladder cancer and the management strategies in the patient journey.

They further discuss relevant patient situations and cover the latest data from EAU and the other recent meetings.

Related Videos

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Hypofractionated high dose intensity modulated radiotherapy non-inferior for...

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK

$Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )$

Moving to the future: Artificial intelligence in surgery

Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal

Moving to the future: Artificial intelligence in surgery ( Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal )

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

Nirogacestat success for desmoid tumours

Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany

Nirogacestat success for desmoid tumours ( Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

More from ecancer